Status:
COMPLETED
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Insulin Sensitivity
Multiple Mitochondrial Dysfunctions Syndrome
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and...
Detailed Description
"Glucotoxicity" has been implicated as a cause of insulin resistance and impaired beta cell function in T2DM. Abundant support for the glucotoxicity hypothesis has been provided by in vivo and in vitr...
Eligibility Criteria
Inclusion
- T2DM
- Drug Naive Or On Oral Therapy
Exclusion
- Insulin Treatment
- Major Organ Disease
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2018
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01439854
Start Date
March 1 2011
End Date
June 30 2018
Last Update
July 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Diabetes Division, UTHSCSA
San Antonio, Texas, United States, 78229